Swedish Orphan Biovitrum
343.00 SEK
+4.26 %
Less than 1K followers
SOBI
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+4.26 %
+6.00 %
+25.18 %
+12.68 %
+8.07 %
+12.75 %
+59.53 %
+112.04 %
+618.80 %
Swedish Orphan Biovitrum operates in the pharmaceutical industry and focuses on the development and distribution of medicines for rare diseases. The company's products are aimed at healthcare institutions and patients with specific medical needs. The business is global with a main presence in Europe, North America and Asia. Swedish Orphan Biovitrum was founded in 1939 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
122.59B SEK
Turnover
169.43M SEK
Revenue
26.03B
EBIT %
21.61 %
P/E
30.17
Dividend yield-%
-
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
5.2
2026
Annual report '25
28.4
2026
Interim report Q1'26
6.5
2026
General meeting '26
All
Press releases
ShowingAll content types
Swedish Orphan Biovitrum AB: Sobi Q3 2025 report: Accelerated growth and portfolio momentum
Swedish Orphan Biovitrum AB: Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools